长效生长激素治疗的理由和未来的方面
Semra Çetinkaya1, Erdal Eren2, Furkan Erdoğan3
1University of Health Sciences Türkiye, Ankara Dr. Sami Ulus Obstetrics and Gynecology, Child Health and Diseases Training and Research Hospital, Clinic of Child Health and Diseases, Ankara, Türkiye
Journal of clinical research in pediatric endocrinology
|March 15, 2024
概括
每天注射复合生长激素 (GH) 给儿科患者带来了坚持的挑战,影响了生长. 长效GH (LAGH) 配方提供了一种方便的替代方案,改善了坚持和治疗结果.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 复合人体生长激素 (GH) 通常通过每日皮下注射进行注射.
- 每日GH治疗对儿科患者和他们的护理人员来说存在重大坚持挑战.
- 缺乏坚持性会导致生长反应不足,可能会影响治疗的延续和补偿.
研究的目的:
- 评估新型长效生长激素 (LAGH) 配方的疗效和安全性.
- 评估LAGH在改善患者舒适性和治疗坚持性方面的潜力.
- 为了比较LAGH与每日GH的生长结果.
主要方法:
- 随机临床试验的综述,比较LAGH配方与每日GH.
- 对生长速度,身体组成和不良事件的数据进行分析.
- 评估患者报告的方便性和坚持性指标.
主要成果:
- 在恢复生长速度和改善身体组成方面,LAGH配方的疗效与每日GH相当.
- 由于剂量不太频繁,LAGH的使用增加了患者和护理人员的便利性.
- 在临床试验中,LAGH配方没有报告任何意想不到的副作用.
结论:
- 长效生长激素 (LAGH) 配方为每日GH注射提供了有效和安全的替代方案.
- 在儿科生长障碍中,LAGH可以显著改善治疗坚持性和患者舒适性.
- 这些新型配方可以确保持续的治疗效益,并支持治疗的持续补偿.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Insulin Formulations: Types and Delivery
193
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
193
Hypoglycemia and Glucagon
259
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
259
Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K


